Hbl- Hadasit Bio-holdings Ltd. · TASE:HDST-M
Hbl- Hadasit Bio-holdings — Hadasit Bio-Holdings — Investor Presentation (April 2015)
26 slides from Hbl- Hadasit Bio-holdings's investor presentation, April 2015
Slide 1: ie) = aa n D = [e) aa adas
ie) = aa n D = 2 [e) aa adas
Slide 2: Legal Clarification
HBL Legal Clarification This presentation does not constitute an offer to purchase Company’s securities or an invitation to receive offers, and is intended to provide only general information, partial in nature, with the aim of providing explanations about the Company to investors and analysts. This
Slide 3: HBL company overview
HBL Founded in 2005, Hadasit Bio-Holdings Ltd. ("HBL") is a publicly-traded holding company (TASE: HDST / OTCQB: HDASY 1:20) We function as a public gateway to the emerging Israeli biotech market, through our longstanding partnership with Hadassah University Medical Center in Jerusalem and by identi
Slide 4: Structure
STRUCTURE 36% Hadasit (100% Hadassah) HBL 55% Public 9% Ciano Investments Ltd. UK Private Equity 21% *26% 6% 49% 70% 66% 4 *20% assuming the notes will be converted
Slide 5: Portfolio Partners
PORTFOLIO PARTNERS HBL 21% 26% 6% 49% 70% 66% Private Group 5
Slide 6: Portfolio Segments
PORTFOLIO SEGMENTS 21% 26% 6% 49% 70% 66% Cell Therapy Cell Therapy & Innovative Dual Signaling Antibodies for Multi Dry AMD Immune Therapy for Drugs Proteins For Autoimmunity Biomarker and CNS Autoimmunity and For CNS Cancer and and Diagnostics For 6 Inflammatory Autoimmunity Inflammatory Colorecta
Slide 7: A gateway to Israeli Biotech
HBL A gateway to Israeli Biotech Experienced, well-respected team affords access to broad network and pipeline of investment and collaboration candidates • Government • Private investors • Established companies • Start-ups 7
Slide 8: The Team
THE TEAM TAMI KFIR YIGAL ERLICH CEO CHAIRMAN Vast experience in investments management, Founder and Managing Partner at the Yozma commercialization and cross-boarder deals. Group, Israel’s first VC fund .Considered a Over 20 years in the biotech industry in various pioneer in Israeli venture capital
Slide 9: HBL - Facts & Figures
HBL - FACTS & FIGURES $32M – Raised to date $23M – Invested in portfolio companies • $15M Received in grants from OCS • $32M Additional investments from strategic partners and investors in portfolio companies 9 Figures updated to 31/12/2014
Slide 10: Hadassah University Hospital
HADASSAH UNIVERSITY HOSPITAL Value Creation through Close Collaboration • Leading research hospital in Israel • Renowned clinicians & clinical trial facilities • #1 in clinical performance in Israel • Proven experience in identifying unmet medical needs 10
Slide 11: The HBL Model
THE HBL MODEL Hadassah Medical Center Clinical TTO-IP trials Commercialization executed by HBL at HMC Screening HBL Funding Startup Companies Management 11
Slide 12: Portfolio
PORTFOLIO © Enlivex Therapeutics Itd = Sy #3 CellCure KAHR Medical Ltd * NewroSciences Ltd. az Innovative Biopharmaceuticals C) BlfoMarCare Technologies Diagnosing Cancer with Care Hadasit Bio-Holdings Ltd.
Slide 13: Enlivex Therapeutics: cell therapy for immune tolerance
Therapeutic focus: Cell therapy solution for immune tolerance induction in autoimmune and inflammatory conditions including graft-versus-host disease (GvHD) in bone marrow transplants, solid organ transplant rejection and Crohn's disease Lead product candidate: ApoCell, granted orphan drug designati
Slide 14: Enlivex market opportunity and investments
Market Opportunity: • GvHD market to reach ~$615 million in 2018 • More than 30,000 bone-marrow transplants annually, approx. 30% of patients develop GvHD Competitive Advantage • Autoimmune diseases (aggregate)> $20 billion Autologous therapy derived from patient’s Investments: $15M own cells enabli
Slide 15: CellCure: OpRegen for dry AMD
Therapeutic focus: Development of cell therapies for retinal and neural degenerative diseases using human embryonic stem cells Lead product candidate: OpRegen®, proven to slow disease progression of severe dry AMD (age-related macular degeneration) Stage: IND application approved by FDA; preparing t
Slide 16: OpRegen market opportunity and investments
Market Opportunity: • No FDA approved therapy for dry AMD • There are about 1.6 million new cases of dry-AMD in the US annually , yearly economic loss in US has been estimated $24.4B Competitive Advantage • Estimated 973,000 AMD patients with potential to benefit from The FDA-approved CellCure thera
Slide 17: KAHR Medical: dual signaling protein
Therapeutic focus: Development of novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases based on its proprietary dual signaling protein (DSP) Lead product candidate: KAHR-102 is a fusion protein that links portions of two immune and cancer-related membrane proteins
Slide 18: KAHR market opportunity and investments
Market Opportunity: • Lymphoma and autoimmune diseases • Comparable drugs for both cancer and autoimmune are being sold for several Billions of US $ annually Competitive Advantage • The market for lymphoma and autoimmune diseases is estimated to be over 30 B of US $ Bi-functional biological drugs of
Slide 19: D-Pharm: THR-18 for CNS conditions
Therapeutic focus: Developing innovative targeted drug for CNS conditions Lead product candidate : THR-18 allows the existing thrombolytic stroke medication to easily dissolve blood clots Stage: A THR-18 phase II/a clinical trial in acute stroke patients taking tPA (Altepase) has been completed succ
Slide 20: ProtAb: Prozumab for IBD
Therapeutic focus: Development of novel therapeutic agents that modulate cytokine regulation, tipping the balance toward anti- inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases Lead product candidate: Prozumab, a promising monoclonal antibody with a unique mech
Slide 21: ProtAb market opportunity and investments
Market Opportunity: • Global IBD market to reach $9.6M in 2017 Competitive Advantage Prozumab is a first-in class humanized anti- Investments: $9.1M HSP60 monoclonal • HBL ($3.6M) antibody utilizing a • Pontifax ($1.65M) unique mechanism of • CBI ($1.65M) action for the treatment • OCS ($2.2M) of au
Slide 22: BioMarCare: Colon-MarCarePlex
Therapeutic focus: Development of a cluster of high value tumor biomarkers for pre-cancer alert, early detection and prediction of colorectal cancer (CRC) risk and response Lead product candidate: Colon-MarCarePlex™, the first IVD plasma RNA test for CRC, based on a panel of biomarkers Stage: Comple
Slide 23: BioMarCare market opportunity and investments
Market Opportunity: • Colon and rectal cancer diagnostics generate ~$3.7 billion in US revenue per year Competitive Advantage High sensitivity and specificity blood based Investments: $3.9M technology offering • HBL ($1.7M) potential alternative to • Micromedic ($1M) invasive diagnostic • OCS ($1.2M
Slide 24: Advancement
Advancement Maturity point for our current portfolio companies for strategic / financial deals Company HBL Lead Opt. Preclinical Phase I Phase IIa Phase IIb/III Enlivex D-Pharm CellCure KAHR 2015 ProtAb BioMarCare Commercial Stages 24
Slide 25: Future Plan
FUTURE PLAN • Leading our current portfolio companies to commercialization by reaching inflection points • Broaden our portfolio with new projects in fields such as pharmaceuticals, medical devices and e-Health • Leverage governmental funds for early stage investments • Establish presence in China t
Slide 26: Thank you
Haddsit Bio-Holdings Ltd.
Hadasit Bio-Holdings — Investor Presentation (April 2015) on 6ix